A case of an unusual subtrochanteric fracture in a patient receiving denosumab

Endocrine Practice

Volumn 19, Issue 3, 2013, Pages

  Paparodis, Rodis ^a   Buehring, Bjoern ^a   Pelley, Elaine M ^a   Binkley, Neil ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; HYDROCHLOROTHIAZIDE;

AGED; ARTICLE; BONE RADIOGRAPHY; CASE REPORT; CHRONIC KIDNEY DISEASE; CORTICAL BONE; DENSITOMETRY; FEMALE; FEMUR SUBTROCHANTERIC FRACTURE; FRACTURE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; INJURY; LEG PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; RISK ASSESSMENT;

AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; HIP FRACTURES; HUMANS; OSTEOPOROSIS;

EID: 84879408894     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP12367.CR     Document Type: Article

References (19)

1. Goldfine AB, Mun E, Patti ME. Hyperinsulinemic hypoglycemia following gastric bypass surgery for obesity. Curr Opin Endocrinol Diabetes. 2006;13:419-424. pag e64-e68 1. Chen JS, Sambrook PN. Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol. 2012;8:81-91.
2. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294-1301.
3. Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecrosis o. The jaw. Nat Rev Rheumatol. 2012;8:90-96.
4. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force o. The American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25:2267-2294.
5. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-342.
6. Delmas PD. Clinical potential of RANKL inhibition fo. The management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom. 2008;11: 325-338.
7. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Eng J Med. 2009;361:756-765.
8. Wong MH, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2012;2:CD003474.
9. Durchschlag E, Paschalis EP, Zoehrer R, et al. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J Bone Miner Res. 2006;21:1581-1590.
10. Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K. Alendronate increases degree and uniformity of mineralization in cancellous bone and decrease. The porosity in cortical bone of osteoporotic women. Bone. 2001;29:185-191.
11. Allen MR, Iwata K, Phipps R, Burr DB. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone. 2006;39:872-879.
12. Kostenuik PJ, Smith SY, Jolette J, Schroeder J, Pyrah I, Ominsky MS. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone. 2011;49:151-161.
13. Brown JP, Prince RL, Deal C, et al. Comparison o. The effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24:153-161.
14. Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures o. The femur. J Bone Miner Res. 2012;27:2544-2550.
15. Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26:1829-1835.
16. Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27:1471-1479.
17. Burke MT, Hollett PR, Gray NA. Atypical fractures associated with bisphosphonate use post-renal transplantation. Nephrology (Carlton, Vic). 2012;17(Suppl 1):1-4.
18. Nickolas TL, Cremers S, Zhang A, et al. Discriminants of prevalent fractures in chronic kidney disease. JASN. 2011; 22:1560-1572.
19. Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use atypical femoral fractures and bisphosphonate use, Arch Intern Med 2012 172